FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022177090> ?p ?o ?g. }

• W2022177090 endingPage "1480" @default.
• W2022177090 startingPage "1475" @default.
• W2022177090 abstract "A relevant percentage of patients with metastatic renal cell carcinoma develop intolerance to vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFr-TKIs) and require careful selection of subsequent treatment. This retrospective analysis evaluated the safety and efficacy of everolimus in patients enrolled in the phase-III RECORD-1 trial who discontinued previous VEGFr-TKI therapy because of toxicity.Patients with an adverse event (AE) as their primary reason for discontinuation of previous VEGFr-TKI therapy were included. Median progression-free survival (PFS) for VEGFr-TKI-intolerant patients in each arm was estimated using the Kaplan-Meier method, and effect on PFS (hazard ratio (HR)) was calculated using the Cox proportional hazard model.In VEGFr-TKI-intolerant patients (n=58, 14%), median PFS was 5.4 months with everolimus and 1.9 months with placebo (HR: 0.32; P=0.004). In sunitinib-intolerant patients (n=26), median PFS was 5.1 months with everolimus and 2.8 months with placebo (HR: 0.28; P=0.033). Grade 3/4 AEs reported with everolimus in VEGFr-TKI-intolerant patients included infections (16%), fatigue (7%) and stomatitis (4%). The toxicity profile of everolimus was similar in the VEGFr-TKI-intolerant and overall study populations.Everolimus is well tolerated and efficacious with no increased toxicity in patients intolerant to VEGFr-TKI therapy." @default.
• W2022177090 created "2016-06-24" @default.
• W2022177090 creator A5001987856 @default.
• W2022177090 creator A5034083208 @default.
• W2022177090 creator A5040832651 @default.
• W2022177090 creator A5049672639 @default.
• W2022177090 creator A5050649350 @default.
• W2022177090 creator A5053701060 @default.
• W2022177090 creator A5059063118 @default.
• W2022177090 creator A5061095811 @default.
• W2022177090 creator A5072800302 @default.
• W2022177090 creator A5085823608 @default.
• W2022177090 creator A5089962252 @default.
• W2022177090 creator A5090509109 @default.
• W2022177090 date "2012-03-22" @default.
• W2022177090 modified "2023-10-17" @default.
• W2022177090 title "Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis" @default.
• W2022177090 cites W1965874702 @default.
• W2022177090 cites W1999966467 @default.
• W2022177090 cites W2008949143 @default.
• W2022177090 cites W2023952988 @default.
• W2022177090 cites W2034058863 @default.
• W2022177090 cites W2055110529 @default.
• W2022177090 cites W2055986313 @default.
• W2022177090 cites W2083378657 @default.
• W2022177090 cites W2104241646 @default.
• W2022177090 cites W2110424712 @default.
• W2022177090 cites W2117125017 @default.
• W2022177090 cites W2118677643 @default.
• W2022177090 cites W2127725920 @default.
• W2022177090 cites W2138129102 @default.
• W2022177090 cites W2139248078 @default.
• W2022177090 cites W2142297664 @default.
• W2022177090 cites W2149456801 @default.
• W2022177090 cites W2162424705 @default.
• W2022177090 cites W2166788033 @default.
• W2022177090 cites W2911611736 @default.
• W2022177090 cites W4234636179 @default.
• W2022177090 doi "https://doi.org/10.1038/bjc.2012.89" @default.
• W2022177090 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3341863" @default.
• W2022177090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22441644" @default.
• W2022177090 hasPublicationYear "2012" @default.
• W2022177090 type Work @default.
• W2022177090 sameAs 2022177090 @default.
• W2022177090 citedByCount "23" @default.
• W2022177090 countsByYear W20221770902012 @default.
• W2022177090 countsByYear W20221770902013 @default.
• W2022177090 countsByYear W20221770902014 @default.
• W2022177090 countsByYear W20221770902015 @default.
• W2022177090 countsByYear W20221770902016 @default.
• W2022177090 countsByYear W20221770902017 @default.
• W2022177090 countsByYear W20221770902018 @default.
• W2022177090 countsByYear W20221770902021 @default.
• W2022177090 crossrefType "journal-article" @default.
• W2022177090 hasAuthorship W2022177090A5001987856 @default.
• W2022177090 hasAuthorship W2022177090A5034083208 @default.
• W2022177090 hasAuthorship W2022177090A5040832651 @default.
• W2022177090 hasAuthorship W2022177090A5049672639 @default.
• W2022177090 hasAuthorship W2022177090A5050649350 @default.
• W2022177090 hasAuthorship W2022177090A5053701060 @default.
• W2022177090 hasAuthorship W2022177090A5059063118 @default.
• W2022177090 hasAuthorship W2022177090A5061095811 @default.
• W2022177090 hasAuthorship W2022177090A5072800302 @default.
• W2022177090 hasAuthorship W2022177090A5085823608 @default.
• W2022177090 hasAuthorship W2022177090A5089962252 @default.
• W2022177090 hasAuthorship W2022177090A5090509109 @default.
• W2022177090 hasBestOaLocation W20221770901 @default.
• W2022177090 hasConcept C126322002 @default.
• W2022177090 hasConcept C141071460 @default.
• W2022177090 hasConcept C142724271 @default.
• W2022177090 hasConcept C143998085 @default.
• W2022177090 hasConcept C197934379 @default.
• W2022177090 hasConcept C204787440 @default.
• W2022177090 hasConcept C207103383 @default.
• W2022177090 hasConcept C27081682 @default.
• W2022177090 hasConcept C2777472916 @default.
• W2022177090 hasConcept C2778019345 @default.
• W2022177090 hasConcept C2778695046 @default.
• W2022177090 hasConcept C2778715236 @default.
• W2022177090 hasConcept C2779490328 @default.
• W2022177090 hasConcept C2779699572 @default.
• W2022177090 hasConcept C44249647 @default.
• W2022177090 hasConcept C71924100 @default.
• W2022177090 hasConcept C90924648 @default.
• W2022177090 hasConceptScore W2022177090C126322002 @default.
• W2022177090 hasConceptScore W2022177090C141071460 @default.
• W2022177090 hasConceptScore W2022177090C142724271 @default.
• W2022177090 hasConceptScore W2022177090C143998085 @default.
• W2022177090 hasConceptScore W2022177090C197934379 @default.
• W2022177090 hasConceptScore W2022177090C204787440 @default.
• W2022177090 hasConceptScore W2022177090C207103383 @default.
• W2022177090 hasConceptScore W2022177090C27081682 @default.
• W2022177090 hasConceptScore W2022177090C2777472916 @default.
• W2022177090 hasConceptScore W2022177090C2778019345 @default.
• W2022177090 hasConceptScore W2022177090C2778695046 @default.
• W2022177090 hasConceptScore W2022177090C2778715236 @default.
• W2022177090 hasConceptScore W2022177090C2779490328 @default.
• W2022177090 hasConceptScore W2022177090C2779699572 @default.

• next